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Abstract
Objective—To assess sildenafil and N-desmethyl sildenafil (DMS) exposure in infants receiving 
sildenafil for the treatment of pulmonary hypertension (PH).
Study design—Data were collected from 6 infants receiving sildenafil for the treatment of PH, 
and plasma samples were collected at the time of routine laboratory blood draws. The 
echocardiography results were assessed for improvement in right ventricular (RV) hypertension 
following sildenafil treatment.
Result—The median (range) sildenafil and DMS concentrations were 27.4 ng/mL (2.6-434.0) 
and 105.5 ng/mL (3.6-314.0), respectively. The median metabolite-to-parent ratio was higher in 
infants receiving co-medications that can induce cytochrome P450 (CYP) enzymes (5.2 vs. 0.7). 
The echocardiography results showed improvement in RV hypertension for the majority of infants 
(5/6).
Conclusion—The concentrations of sildenafil and DMS were within the previously observed 
ranges. Our results suggest that caution may be warranted when CYP-related co-medications are 
administered during sildenafil treatment for PH.
Introduction
Sildenafil is a phosphodiesterase type-5 inhibitor approved in adults for the treatment of 
pulmonary hypertension (PH). Sildenafil-mediated inhibition of phosphodiesterase type-5 
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leads to an increase in intracellular cyclic guanosine monophosphate, which results in 
pulmonary vasodilation.1,2 In infants, PH affects term infants (often called persistent 
pulmonary hypertension of the newborn) and premature infants with bronchopulmonary 
dysplasia and associated pulmonary arterial hypertension.3–5 Few clinical studies have 
evaluated the pharmacokinetics (PK) and use of sildenafil in infants, yet the use in premature 
infants is increasing.6 In 2012, the Food and Drug Administration issued a black box 
warning for sildenafil use in children (ages 1 through 17 years). Despite this warning, 
sildenafil is still used in infants with bronchopulmonary dysplasia and pulmonary arterial 
hypertension. The relationship between sildenafil dosing, safety, and efficacy in infants is 
currently unclear, and further studies are required to better understand sildenafil disposition 
in infants.
In adults, the PK of sildenafil have been extensively investigated. Sildenafil is highly protein 
bound (96%) and is distributed throughout the body (volume of distribution=1-2 L/kg).7,8 
After oral administration, the apparent terminal elimination half-life of sildenafil in adults is 
3-5 hours,8–10 and it undergoes almost complete hepatic metabolism.11,12 The major 
circulating metabolite of sildenafil is N-desmethyl sildenafil (DMS), which is active and is 
reported to have 50% in vitro potency of sildenafil.11 Previously published studies have 
reported that the major pathways of sildenafil biotransformation are cytochrome P450 (CYP) 
enzymes 3A4 (CYP3A4) (∼80%) and 2C9 (CYP2C9) (∼20%).11,12 Currently, limited 
information exists about the impact of ontogeny of CYP enzyme on the PK of sildenafil in 
infants.
Few studies have evaluated the PK of sildenafil in term infants and none in premature 
infants.13,14 This is due to the challenges associated with conducting clinical trials in infants, 
including limited vascular access for PK sampling and blood volumes. Opportunistic study 
designs can help overcome these challenges by capitalizing on blood sampling from 
standard medical care procedures.15–18
In this opportunistic study, we collected data from six infants (five premature and one full-
term) to evaluate the disposition of sildenafil and DMS.
Methods
Patient population
From 2010-2012, plasma samples were collected from infants receiving sildenafil enterally 
(by nasogastric tube) for the treatment of PH at the time of routine blood draws as part of 
standard of care labs. All infants were enrolled at the Newborn Critical Care Center at The 
University of North Carolina at Chapel Hill Children's Hospital. The following information 
was collected for each infant enrolled: gender, gestational age, postnatal age, and weight at 
first dose and concomitant medications (only systemically administered drugs with known 
interactions with the CYP450 pathways). The study protocol was reviewed and approved by 
the University of North Carolina at Chapel Hill Institutional Review Board (IRB number: 
10-0865). Written informed consent was obtained from the parent/guardian of each infant 
for use of the opportunistic data for research purposes.
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Dosing and sample collection
Dosing information was obtained for at least five doses prior to the plasma samples collected 
for PK analyses. Because this was an opportunistic study design, the dosing varied and was 
determined by the treating clinician, not by protocol. In addition, PK sample collection was 
performed during time of routine blood draws as ordered by the treating physician, and thus 
occurred at differing time intervals. Samples were collected and stored at -80°C until further 
analysis. Echocardiography data were collected in all six infants.
Determination of sildenafil and DMS plasma concentrations
A liquid chromatography-tandem mass spectrometry (LC/MS/MS) analysis was performed 
by Covance Laboratories Inc. (Madison, WI). Plasma samples were analyzed for 
concentrations of sildenafil and DMS using an LC/MS/MS detection system comprising a 
Shimadzu HPLC and API 4000 QTRAP mass spectrometer (Applied Biosystems, Carlsbad, 
CA). Sildenafil-d8 and N-desmethyl sildenafil-d8 were used as internal standards for 
sildenafil and DMS, respectively. The standards were prepared in plasma. The assay 
accuracy ranged from 100.2% to 107.3% for sildenafil and -96.1% to 110% for DMS. 
Method imprecision for plasma quality control samples at concentrations of 3, 30, and 350 
ng/mL was 0.9, 1.5, and 9.81% coefficient of variation (CV), respectively, for sildenafil, and 
7.95, 3.78, and 0.02% CV, respectively, for DMS. The lower limit of quantification for 
sildenafil and DMS in human plasma was 1 ng/mL for both analytes (range: 1-500 ng/mL 
for sildenafil and DMS). Peak areas were integrated and analyzed using Analyst software 
(version 1.5.1; Applied Biosystems, Carlsbad, CA).
Data analysis
The sildenafil and DMS concentrations and the metabolite-to-parent ratios (calculated from 
individual data points) for each infant were analyzed.
Results
Patient characteristics
Six infants were enrolled; the median (range) gestational age was 25.6 weeks (23.6-38.7, 
Table 1). The median (range) body weight and postnatal age at the start of first dose were 3.2 
kg (2.0-5.9) and 145 days (10-209), respectively. Sildenafil dose varied with time in different 
infants, with a median dose of 3 mg (1.5-9.2) or 0.92 mg/kg (0.5-2.1). Overall, five samples 
for each infant were collected and analyzed for sildenafil and DMS concentrations. The 
sample collection times varied between infants, ranging from 0-11 hours after the last dose.
During sildenafil treatment, all infants were receiving concomitant medications, and four out 
of six infants were administered inducers of CYP3A4 and CYP2C9 (dexamethasone and 
phenobarbital) (Table 1).
The echocardiography data were obtained and the right ventricular (RV) pressure was 
evaluated in the infants. The majority of infants (five out of six) showed improvement in RV 
hypertension with time following sildenafil treatment.
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Pharmacokinetics
A total of 30 samples were collected from all infants, and all but one sample were above the 
lower limit of quantification. The median (range) of concentration values obtained for 
sildenafil and DMS in all infants were 27.4 ng/mL (2.6-434.0) and 105.5 ng/mL (3.6-314.0), 
respectively. A high metabolite-to-parent ratio was observed in infants who were receiving 
additional drugs known to induce CYP enzymes (Table 2). The median (range) metabolite-
to-parent ratio for infants receiving no CYP-related co-medications (infants 3 and 5) was 0.7 
(0.3-1.0) versus 5.2 (1.1-14.5) for those receiving CYP-related co-medications.
Discussion
In this opportunistic study, we assessed the concentrations of sildenafil and DMS in infants 
who were undergoing treatment for PH. The observed concentrations of sildenafil and DMS 
were within the range of values that were previously reported.14 Our results suggest that 
potential CYP-mediated drug interactions may play an important role in the disposition of 
sildenafil.
PH is a devastating cardiopulmonary complication in premature infants with 
bronchopulmonary dysplasia and full-term infants with persistent pulmonary hypertension 
of the newborn. Sildenafil is frequently prescribed to both of these populations without 
adequate safety and efficacy information. Neonatologists generally use echocardiograms to 
diagnose and monitor PH in infants, as there are no validated tests to evaluate the severity of 
PH in infants (such as the walking test in adults).19,20 Regardless, the echocardiography 
results from our study demonstrated that the majority of infants (five out of six) had 
improvement in RV hypertension, which is consistent with a recent study in premature 
infants treated with sildenafil for bronchopulmonary dysplasia and PH.21 These authors 
reported that although an echocardiographic improvement occurred in the majority of 
infants, fewer infants had clinical improvement.21 Taken together, these data support the idea 
that sildenafil may be of therapeutic benefit, and future studies should focus on the optimal 
dose, schedule, and duration in this vulnerable population. Catheterization studies 
sometimes show large differences between measured RV pressure and that estimated from a 
tricuspid regurgitant jet velocity from echocardiogram. Finally, there is a need to validate the 
use of echocardiography as an appropriate pharmacodynamic endpoint to diagnose and 
monitor PH in infants and assess the adequacy of PH treatment in infants.
A previous study assessed the population PK of intravenously administered sildenafil in term 
infants up to 7 days of age.13 Another report investigated the PK of sildenafil after enteral 
administration in neonates.14 However, high interpatient variability was associated in both of 
these studies.13,14 In our study, due to the small sample size, overall sparseness of the data, 
and poor reliability of sildenafil dosing times from the medical records, we were unable to 
perform a formal PK analysis. Thus, sildenafil and DMS exposure values were compared to 
previously reported values from a PK study of sildenafil administered enterally in 
neonates.14 The concentrations of sildenafil and DMS observed in our study were within the 
approximate concentration ranges observed in the previous study.14
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Our results show that higher metabolite-to-parent ratios were observed in infants receiving 
co-medications that are inducers of CYP3A4 and CYP2C9 as compared to infants who did 
not receive any CYP-related co-medications (Table 2). Little is currently known regarding 
the effect of ontogeny of CYP enzymes on the disposition of sildenafil, especially in 
premature infants. Previous in vitro studies have shown that the downregulation of CYP3A7 
(a fetal CYP3A isoform) and concurrent upregulation of CYP3A4 and expression of 
CYP2C9 in fetal livers increase rapidly within 1 month after birth.22–24 In line with these 
findings, one study reported an increase in sildenafil clearance in the first week of life after 
intravenous sildenafil administration in term infants.13 Collectively, these findings support 
that sildenafil levels should be carefully monitored in infants with PH when CYP-related co-
medications are administered.
Although sildenafil is widely used in clinic for the treatment of PH in infants, limited PK 
studies have been performed to inform its dosing. This may be due in part to the general 
challenges associated with performing clinical trials in infants and special population of 
interest. One way to overcome these challenges is the use of opportunistic study designs that 
can provide valuable information from standard medical care procedures. Such opportunistic 
clinical trial designs have been successfully implemented to evaluate the PK of several drugs 
in full-term and premature infants.15–18 Our use of an opportunistic clinical trial design 
allowed us to gain a better understanding of sildenafil disposition in infants being treated for 
PH.
In summary, our observed concentrations of sildenafil and DMS were within the previously 
reported concentration ranges in older children.14 Although echocardiography observations 
have suggested that sildenafil treatment leads to a therapeutic benefit, it is unclear whether 
this is the natural course of the disease or whether sildenafil was actually beneficial. Our 
findings suggest that caution may be warranted in infants receiving CYP-related 
concomitant medications with sildenafil for treatment of PH. Further PK, safety, and 
efficacy studies are needed to optimize the dose and indication for sildenafil in premature 
infants with PH.
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Table 2
Doses, observed concentrations of sildenafil and N-desmethyl-sildenafil (DMS), and 
metabolite-to-parent ratios
Infant Median dose (mg) (range)
Median sildenafil concentration 
(ng/mL) (range)
Median DMS concentration 
(ng/mL) (range)
Median metabolite-to-
parent ratio (range)
1 1.5 (1.5-5.0) 22.7 (2.6-37.6) 108.0 (10.4-171.0) 4.2 (3.1-7.5)
2 3.6 21.5 (7.1-30.0) 168.0 (103.0-247.0) 8.5 (7.7-14.5)
3 3.0 25.4 (5.5-35.4) 14.8 (3.6-28.0) 0.7 (0.3-0.8)
4 3.7 (2.5-8.0) 26.5 (9.4-40.7) 111 (10.2-249.0) 5.9 (1.1-8.8)
5 3.9 (2.6-3.9) 114.0 (35.6-434.0) 82.4 (32.0-120.0) 0.7 (0.3-1.0)
6 8.6 (6.4-9.2) 54.4 (21.7-162.0) 172 (102.0-314.0) 3.2 (1.9-5.1)
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